ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 110,28
0,16%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vivos Therapeutics Inc (VVOS)

  7. Vivos Therapeutics Inc (VVOS) Actualités

VVOS Vivos Therapeutics Inc

2,25
-0,20 (-8,16%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Vivos Therapeutics Inc VVOS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,20 -8,16% 2,25 06:00:09
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,43 2,24 2,4694 2,25 2,45
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202422:15EDGAR2Form 8-K - Current report
12/6/202413:30GLOBEVivos Therapeutics Closes $7.5 Million At-The-Market Private..
20/5/202419:04GLOBEConsolidated Water Comments on ISS and Glass Lewis Reports..
17/5/202422:43EDGAR2Form 8-K - Current report
15/5/202420:54EDGAR2Form 8-K - Current report
14/5/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:05GLOBEVivos Therapeutics Reports First Quarter 2024 Financial..
14/5/202413:30GLOBEVivos Therapeutics Schedules Release of First Quarter 2024..
09/4/202413:30GLOBEVivos Therapeutics’ Flagship CARE Oral Medical Devices..
28/3/202421:05GLOBEVivos Therapeutics Reports Fourth Quarter and Full Year 2023..
28/3/202412:30GLOBEVivos Therapeutics Schedules Release of Fourth Quarter and..
15/2/202414:55EDGAR2Form 8-K - Current report
15/2/202414:00GLOBEVivos Therapeutics Announces Exercise of Warrants for..
14/2/202423:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202413:30GLOBEVivos Therapeutics Highlights Significant Favorable Market..
08/1/202413:30GLOBEVivos Therapeutics Sees Positive Preliminary Metrics..
11/12/202313:30GLOBEVivos Therapeutics Presents Groundbreaking Event:..
04/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
01/12/202322:12EDGAR2Form 424B1 - Prospectus [Rule 424(b)(1)]
30/11/202322:05EDGAR2Form 8-K - Current report
30/11/202322:03EDGAR2Form S-1/A - General form for registration of securities..
29/11/202313:30GLOBEVivos Therapeutics Receives First Ever FDA 510(k) Clearance..
22/11/202322:46EDGAR2Form S-1 - General form for registration of securities under..
14/11/202322:05GLOBEVivos Therapeutics Reports Third Quarter 2023 Financial..
09/11/202322:30GLOBEVivos Therapeutics Schedules Release of Third Quarter 2023..
03/11/202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/11/202322:10EDGAR2Form 8-K - Current report
02/11/202322:00GLOBEVivos Therapeutics Closes $4 Million Private Placement
31/10/202313:00GLOBEVivos Therapeutics Announces Pricing of $4 Million Private..
27/10/202322:15EDGAR2Form 8-K - Current report
26/10/202313:30GLOBEVivos Therapeutics Announces Reverse Stock Split
24/10/202313:30GLOBEVivos Therapeutics Signs Nationwide Distribution Agreement..
11/10/202313:30GLOBEVivos Therapeutics to Begin Clinical Trial at Stanford..
05/10/202313:30GLOBEVivos Therapeutics Announces Strategic Collaboration in the..
04/10/202321:55APSBiotech Soars On New Agreements
04/10/202313:30GLOBEVivos Therapeutics Executes Strategic Agreements with Ormco..
02/10/202313:30GLOBENew York Times Best-Selling Author James Nestor to Headline..
25/9/202315:00EDGAR2Form 8-K - Current report
21/9/202323:10EDGAR2Form 8-K - Current report
14/9/202322:38EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/9/202323:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202315:00EDGAR2Form DEF 14A - Other definitive proxy statements
21/8/202315:00EDGAR2Form 8-K - Current report
16/8/202322:45EDGAR2Form PRE 14A - Other preliminary proxy statements
16/8/202322:30EDGAR2Form 8-K - Current report
16/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/8/202322:05GLOBEVivos Therapeutics Reports Second Quarter 2023 Financial..
16/8/202313:30GLOBEVivos Therapeutics Reschedules Second Quarter 2023 Financial..
14/8/202323:06GLOBEVivos Therapeutics to Reschedule Second Quarter 2023..
11/8/202302:31GLOBEVivos Therapeutics Schedules Release of Second Quarter 2023..

Dernières Valeurs Consultées

NASDAQ
VVOS
Vivos Therapeutics
LSE
BU13
Citi Fun 25
BIT
F29049
Vontobel Financial Produ...
BOV
JFEN1F
JOAO FORTES ON
USOTC
PORTU
Southport Acquisition (PK)
TG
A3LCWT
Banque Fdrative du Crdit...
BIT
P1X138
NLBNPIT1X138 20240918 18...
USOTC
PTSH
PTS (CE)
NASDAQ
MEACW
SEP Acquisition
COIN
NIHLBTC
TSXV
SEI
Sintana Energy
USOTC
DSYOF
Daisyo Corp Ordinary Sha... (PK)
BIT
P1QLG1
BNP Paribas Issuance
BIT
MNL
Monnalisa
BIT
P1R403
BNP Paribas Issuance
BIT
P1PLM1
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés